The Maryland Prescription Drug Affordability Board voted Monday to move forward with setting upper payment limits on the diabetes drug Jardiance, putting into motion the mechanics to put the first state regulations on a drug since the panel’s inception.
With the vote, the limit will now move to a 30-day public comment period before getting a final vote and becoming policy. The limit will impact state and local government health plans starting 2027, effectively setting a ceiling on what the state says it will pay for the drug. The rule will save about $320,000 a year.
In 2028, the drug will be eligible for limits on all insurance plans in Maryland, potentially saving customers millions of dollars in total…